Replies to post #1154 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

> VRUS / Roche – Does anyone know what type of terms they [VRUS] have [for R7128] and what it says for Roche's own Polymerase [R1626] (last I recall there was talk of perhaps them trying a lower dose)?<

Here’s what it says about the R7128 collaboration in VRUS’ S-1/A SEC filing dated 4/27/07:

>>
Under this collaboration, Roche will reimburse us for all of the currently expected external expenses (up to an agreed-upon amount) associated with, and we will be responsible for, certain preclinical work, the IND filing, and the initial clinical trial. Roche will fund all of the expenses of, and be responsible for, other preclinical studies, future clinical development and commercialization of R7128.

…We are developing R7128 under a collaborative licensing agreement that we entered into with Roche in October 2004. We are dependent on Roche to continue the development of R7128 and successfully commercialize it. Roche may terminate its agreement with us without cause on six months’ notice.
<<

R1626, Roche’s in-house HCV polymerase inhibitor, does have some problems (#msg-19006768). Regards, Dew